Did BMS set up a subsidiary to avoid paying $1.4B in U.S. taxes? The Senate finance chairman is on the case

Tax avoidance allegations have hovered over major players in the pharmaceutical industry for decades. Some of the biggest names in the business have occasionally faced inquiries or have had to pay up to the Internal Revenue Service. Now, Bristol Myers Squibb is at the center of a U.S. Senator's tax probe.